Mike Clarke, MD
Dr. Clarke is the Karel and Avice Beekhuis Endowed Professor in Cancer Biology and the Associate Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Dr. Clarke is a board-certified Medical Oncologist. Dr. Clarke is an expert in the field of stem cell biology and has published more than 100 peer reviewed papers in journals including Nature, Science, Cell and the New England Journal of Medicine. Dr. Clarke identified the first molecular pathway that regulates the maintenance and production of adult stem cells and was the first to identify and characterize cancer stem cells in solid tumors. He has much experience in startups and has been an academic founder of three successful early stage companies: Oncomed Pharmaceuticals, Quanticel Pharmaceuticals and AASTROM biosciences. Oncomed was acquired by Mereo Biopharma and Quanticel was acquired by Celgene. Dr. Clarke received his medical training at Indiana University Medical Center as well as the University of Missouri Medical Center and has held academic appointments at the NIH.
Stephen Quake, DPhil
Dr. Quake is the Lee Otterson Professor at Stanford University and is co- President of the Chan Zuckerberg Biohub, president of the CZ Biohub Network, and most recently Head of Science of the Chan Zuckerberg Initiative. His distinguished research career has spanned the gamut from biotechnology tools to novel diagnostics to therapeutics. The practical applications of Dr. Quake’s research have led to more than 130 issued U.S. patents, as well as numerous international patents. Quake is an active entrepreneur who has founded or co-founded several companies, including Fluidigm (IPO), Helicos (IPO), Verinata Health (acquired by Illumina), Moleculo (acquired by Illumina), Immumetrix (merged with XdX followed by IPO as CareDX), Quanticel Pharmaceuticals (acquired by Celgene), Cellular Research (acquired by Becton Dickinson), Karius (private), Agenovir (acquired by Vir) and Molecular Stethoscope (private). Dr. Quake received his doctorate degree at Oxford University in England and completed his post-doctoral fellowship at Stanford University.
Stephen L. Eck, MD, PhD
Dr. Eck is the Senior Vice President, Clinical Development & Chief Medical Officer at MacroGenics, Inc. Prior to MacroGenics, Dr. Eck served as Chief Medical Officer of Immatics US and as President and Chief Executive Officer of Aravive Biologics. Prior to these roles, Dr. Eck was Vice President and Global Head of Oncology Medical Sciences at Astellas Pharma, managing a portfolio of assets which included enzalutamide (Xtandi®), erlotinib (Tarceva®) and gilteritinib (Xospata®). Dr. Eck has also held leadership positions in drug development as Vice President of Translational Medicine and Pharmacogenomics at Eli Lilly and as Head of Clinical Oncology at Pfizer. He began his professional career at Monsanto in cancer target discovery and later joined the University of Pennsylvania, where he was the Anne B. Young Assistant Professor of Cancer Research and the Director of the Cancer Gene Therapy Program. Dr. Eck currently serves as a director for Luminex Corporation (NASDAQ: LMNX) and Circulogene, and on the boards of directors for the Personalized Medicine Coalition and the Central Pennsylvania Clinic. He is also a fellow of the American Association for the Advancement of Science. Dr. Eck holds a Ph.D. from Harvard University and an M.D. from the University of Mississippi School of Medicine with Residency and Fellowship training at the University of Michigan.
Jeff Stafford, PhD
Dr. Stafford has held research and executive management roles in both large pharma and privately held biotech for over 3 decades. He is currently the CEO and cofounder of 858 Therapeutics. Prior to that, he was the founding CSO of Quanticel Pharmaceuticals (later acquired by Celgene) where he led the development of the program which became TACH101. He also held senior scientific and management positions at Takeda San Diego, Syrrx and GlaxoSmithKline, and was founding CEO of Jecure (acquired by Genentech). Dr. Stafford has led discovery teams responsible for the discovery of three FDA-approved drugs – Votrient™ (pazopanib); Nesina™ (alogliptin); and Byfavo™ (remimazolam) – and several others in clinical trials.
HEATH LUKATCH, PHD
Dr. Lukatch is a highly regarded and accomplished life science industry investor. His 36 career investments have resulted in 22 value-creating exits including 11 companies entering the public market and 11 being acquired. He is the co-founder of Red Tree Venture Capital and serves as the firm’s managing partner. From 2015-2020, Dr. Lukatch worked at TPG where he was partner, managing director and life sciences investment team leader in TPG’s Biotech, Growth and RISE platforms. In 2006, Dr. Lukatch co-founded Novo Ventures’ San Francisco office, where he was a partner through 2015. Prior to joining Novo Ventures, Dr. Lukatch was a managing director responsible for biotechnology venture investments at Piper Jaffray Ventures and SightLine Partners. Dr. Lukatch currently serves as chairman of Acrigen Biosciences and Magnus Medical and serves on multiple life sciences company boards. Dr. Lukatch received his Ph.D. in Neuroscience from Stanford University and his B.A. in Biochemistry from the University of California at Berkeley.